Inogen Inc.’s stock value plummeted after its most recent earnings call where the company’s CEO seemed to acknowledge it did not trust its own research firm that gave it a glowing market report and prospective analysis. However, the company is still sticking by some of the projections it predicted last year, despite concerns it will not be able to meet its long-term profit goals.
The maker of portable oxygen concentrators (POC) has come under scrutiny from the short-seller Muddy Waters for inflating its future projections. While Inogen has stated its market potential is about 3 million patients and it expected an annual growth of 7% to 10%, the short seller argues its total addressable market (TAM) size is closer to 1.3 million patients and the market is actually shrinking at a rate of 2.6% annually
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?